ClinicalTrials.gg
RecruitingNCT07525635Updated May 18, 2026

Aspirin Dosing in Pregnancy

An Early Phase 1 interventional study of Aspirin in Preeclampsia Possible, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by NYU Langone Health · Early Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 52 studies testing aspirin in Pre-Eclampsia — 18 open to participants now, 22 under way, 5 of them phase 3. Aspirin · Pre-Eclampsia.

Planned enrollment
48th of 52
30 · median 235
Started
2026
with 3 others
Phase 1
4 of 52
2 open now
Primary completion
2027-08
later than 14 of 21 live
Registered
50th of 52
by date

Among the 52 studies testing aspirin in Pre-Eclampsia, this one is the 48th largest by planned enrollment, is one of 4 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 14 of the 21 other live ones, and was the 50th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

18 of the 52 studies testing aspirin in Pre-Eclampsia are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing aspirin in Pre-Eclampsia, or all of them as a file.
02

Study summary

The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.

03

Conditions studied

  • Preeclampsia Possible

Browse trials for

Keywords

  • Asprin
  • Pregnancy
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant people prior to 17 weeks
  • Prenatal care at NYU Langone Health Obstetrics and Gynecology Associates
  • Age 18-50 years
  • Singleton viable gestation
  • Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for aspirin prophylaxis for preeclampsia based on clinical risk factors.

Exclusion criteria

Exclusion Criteria:

  • Undergoing glucose challenge test (GCT) at time of blood draw
  • Allergy or intolerance to aspirin
  • Antithrombotic or antiplatelet therapy
  • Anemia ( \<10 g/dl) or thrombocytopenia ( count \<100,000), or thrombocytosis (platelet count >600,000)
  • Known hemorrhagic diathesis
  • Planned delivery outside of NYU
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Twice daily dosing of Aspirin

    Participants will take 81mg Aspirin orally, twice daily (162mg total) for 4 weeks and then return to the dosing regimen as prescribed by the discretion of their treating physician.

    Drug: Aspirin

Interventions

  • 81mg twice a day (162mg total)

    Also known as: Acetylsalicylic acid

06

What researchers measure

Primary outcomes

  1. Measures of platelet aggregation assessed by Light Transmission Aggregometry (LTA)

    Time frame: Baseline, 4 weeks after initiation of aspirin

Secondary outcomes

  1. Change in serum thromboxane

    Time frame: Baseline, 4 weeks after initiation of aspirin

  2. Change in complete blood count

    Time frame: Baseline, 4 weeks after initiation of aspirin

  3. Change in Mean Platelet Volume (MPV)

    Time frame: Baseline, 4 weeks after initiation of aspirin

  4. Change in Platelet Distribution Width (PDW)

    Time frame: Baseline, 4 weeks after initiation of aspirin

  5. Change in Plateletcrit (PCT)

    Time frame: Baseline, 4 weeks after initiation of aspirin

  6. Change in Life's Essential 8 questionnaire

    Life's Essential 8 (LE8) is a cardiovascular health scoring system from the American Heart Association that rates health from 0 to 100 based on diet, activity, smoking, sleep, BMI, cholesterol, blood sugar, and blood pressure. Scores indicate high cardiovascular health, 50-79 is moderate, and below 50 is low. A score of 100 is ideal, while 0 represents the lowest health condition, such as severe, uncontrolled risk factors.

    Time frame: Baseline, 4 weeks after initiation of aspirin

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: lucia.muzzarelli@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to lucia.muzzarelli@nyulangone.org To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2027, 15 months after the start.

Of 20 phase 1 interventional studies under Pre-Eclampsia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 13, 2026
StartActual
Apr 27, 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Feb 20, 2028
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07525635
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Apr 27, 2026
Primary completion
Aug 1, 2027 (estimated)
Completion
Feb 20, 2028 (estimated)
Last update
May 18, 2026

Study contacts

Christina A. Penfield, MD, MPH
Contact
Christina.Penfield@nyulangone.org
646-754-2700
Lucia Muzzarelli
Contact
Lucia.Muzzarelli@nyulangone.org
646-754-2760
Christina A. Penfield, MD, MPH
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion